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Abstract
Background—Nucleoside reverse transcriptase inhibitors (NRTIs) are often included in 
antiretroviral (ARV) regimens in treatment-experienced patients in the absence of data from 
randomized trials.
Objective—To compare treatment success between participants who omit versus Add NRTIs to 
an optimized ARV regimen of three or more agents.
Design—Multisite, randomized, controlled trial.
Setting—Outpatient HIV clinics.
Participants—HIV-infected patients with three-class ARV experience and/or viral resistance.
Intervention—Open-label optimized regimens (not including NRTIs) were selected based upon 
treatment history and susceptibility testing. Participants were randomized to Omit or Add NRTIs.
Measurements—The primary efficacy outcome was regimen failure through week 48, using a 
non-inferiority margin of 15%. The primary safety outcome was time to initial episode of severe 
sign/symptom or laboratory abnormality prior to discontinuation of NRTI assignment.
Results—360 participants were randomized and 93% completed a week 48 visit. The cumulative 
probability of regimen failure was 29.8% in the Omit NRTI arm versus 25.9% in the Add NRTI 
arm (difference= 3.2%: 95% CI, −6.1 to 12.5). There were no significant differences in the 
primary safety endpoints or the proportion of participants with HIV RNA <50 copies/mL between 
arms. No deaths occurred in the Omit NRTIs arm, compared with 7 deaths in the Add NRTIs arm.
Limitations—Non-blinded study design and may not be applicable to resource poor settings.
Conclusion—HIV-infected treatment-experienced patients starting a new optimized regimen 
can safely omit NRTIs without compromising virologic efficacy. Omitting NRTIs will reduce pill 
burden, cost, and toxicity in this patient population.
INTRODUCTION
Guidelines for treatment of ARV-experienced HIV-infected patients who are failing therapy 
recommend using a new regimen that combines at least 2, and preferably 3, fully active 
medications to suppress viral replication (1-2). Recommendations regarding which agents to 
use are lacking and fully active medications may not be available due to drug resistance. 
When starting a new regimen in ARV-experienced patients, the standard of care includes 
nucleoside/tide reverse transcriptase inhibitors (NRTIs) even though ARV-experienced 
patients have HIV isolates with mutations that significantly compromise NRTI activity. If 
NRTIs do not contribute to virologic suppression in a well-constructed regimen, their 
inclusion will only add to the pill burden, cost, and potential toxicity.
The availability of several newer ARV agents, which act on targets distinct from the NRTIs, 
has enabled clinicians to construct regimens using drug resistance assays that include more 
Tashima et al. Page 2













than two active drugs without using NRTIs. These newer non-nucleoside reverse 
transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transfer 
inhibitors (INSTIs) and entry inhibitors (EIs) can be combined to construct optimized 
regimens. We hypothesized that, in the setting of a continuous phenotypic susceptibility 
score (cPSS) of >2 (a research measure of ARV activity), a new regimen that omitted NRTIs 
would not be inferior to the addition of NRTIs. We designed AIDS Clinical Trials Group 
(ACTG) A5241 (OPTIONS), a multicenter, randomized, open-label, prospective study, to 




The OPTIONS trial (ACTG A5241) is an open-label, prospective randomized study 
evaluating the benefits and risks of omitting versus adding NRTIs to a new optimized ARV 
regimen (3). The study population consists of HIV-infected individuals failing a PI-based 
regimen with triple class experience (NNRTIs, NRTIs and PIs) or viral resistance. 
Participants were randomly assigned to receive an optimized regimen (Omit NRTIs Arm) or 
to add NRTIs (Add NRTIs Arm) to the optimized regimen. Optimized regimens and NRTI 
regimens were constructed based upon treatment history, viral resistance and co-receptor 
tropism tests (performed by Monogram Biosciences -PhenoSense GT® and Trofile®).The 
planned primary outcome was regimen failure defined as virologic failure or randomized 
NRTI arm assignment change evaluated through 48 weeks. Two important changes to the 
study design included: introduction of the enhanced Trofile® assay (Monogram 
Biosciences, Inc.) on June 13, 2008 that increased the sensitivity to be able to detect non-R5 
using virus by using the complete gp160 coding region of the HIV-1 envelope protein with 
CLIA validation experiments demonstrating success at detecting 0.3% CXCR4-using minor 
variants; and on April 8, 2009 extending follow up through week 96 to allow for evaluation 
of the durability of treatment (data not presented). The Institutional Review Board at each 
participating site approved the study protocol. Written informed consent was obtained from 
all participants in compliance with human experimentation guidelines (U.S. Department of 
Health and Human Services).
Study Participants and Eligibility Criteria
Study participants were recruited from 62 outpatient medical clinics into the trial centers 
across the United States recruited from March 2008 through May 2011 with follow-up 
through 48 weeks (May 31, 2012). The study population included HIV-1-infected 
individuals who were at least 16 years of age, with plasma HIV RNA levels ≥1000 
copies/mL while taking a PI-containing ARV regimen, who had prior experience or 
evidence of resistance to NRTI and NNRTI agents, and had acceptable laboratory values 
including a calculated creatinine clearance ≥50 mL/minute. Persons were ineligible if they 
had active hepatitis B infection, were pregnant or breastfeeding, or were using prohibited 
medications. A key criterion for randomization was that an individualized regimen with 
cPSS>2.0 could be constructed using approved ARV medications excluding NRTIs. A cPSS 
score (0=not susceptible to 1=susceptible) was calculated (see Supplement Table 1) or 
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assigned for each drug in a potential regimen based on participant’s prior drug exposure, 
virus susceptibility, and tropism result. The regimen cPSS was then calculated by adding 
together the cPSS for each drug in the regimen (Note: cPSS is largely a research tool). For 
complete details on inclusion and exclusion criteria see Supplement Table 2.
Randomization and Intervention
Participants were randomized to Omit or Add NRTIs after choosing an optimized regimen 
and NRTI regimen. The centralized, computer-based permuted blocked randomization 
(blocks of 4) was stratified by enfuvirtide (ENF) or INSTI experience (any vs. none), choice 
of a maraviroc (MVC)-containing regimen (yes/no) and NRTI susceptibility (susceptible to 
none vs. susceptible to 1 or more NRTIs). NRTI susceptibility for stratification was defined 
by the ‘Net Assessment’ among the entire panel of NRTIs tested in the genotype/phenotype 
resistance test performed at screening. Prior to randomization, a cPSS was calculated for 
each participant for twenty different optimized regimens. One or more optimized regimens 
with a cPSS above 2.0 and NRTI regimens were recommended by the study team and sent to 
sites for selection prior to randomization. Site investigators and study participants selected 
an optimized regimen and NRTI regimen. Regimen recommendations were influenced by 
any prior intolerance or allergy to ARVs and the participant’s willingness to use ENF. 
Typically sites received recommendations for between one to six optimized regimens and 
three to four NRTI combinations in a prioritized order from the study team (the number of 
options was dependent upon the cPSS of each potential regimen). Twenty possible twice-
daily optimized regimens(3-4) consisting of 3-4 medications (not counting ritonavir), taken 
orally twice daily unless otherwise noted, were composed from the following drugs: 600 mg 
of darunavir (DRV; Janssen Pharmaceuticals, Inc.) with 100 mg of ritonavir (RTV; Abbvie), 
90 mg enfuvirtide by subcutaneous injection (ENF; Roche Pharmaceuticals, Inc.), 200 mg of 
etravirine (ETR; Janssen Pharmaceuticals, Inc.), 400 mg of raltegravir (RAL; Merck & Co., 
Inc.), and 500 mg of tipranavir (TPV; Boehringer Ingelheim) with 200 mg of ritonavir; 
maraviroc (MVC; ViiV Healthcare) was given as 150 mg, 300 mg or 600 mg twice daily – 
depending on other drugs in the regimen -- according to package insert recommendations 
(4). Placebos were not used and all drugs were open-label (site investigators and participants 
were not blinded).
Outcomes and Follow-up
Study evaluations were completed before entry, at entry, at weeks 1, 4, 8, 12, 16, and 24, 
and every 12 weeks thereafter for the duration of study follow-up in all participants. 
Treatment adherence was assessed by self-report at every visit by a standardized 
questionnaire. Adherence counseling was recommended by the study team to include pill/
vial counts from returned bottles and vials of ENF. The primary efficacy outcome was 
regimen failure through 48 weeks, a composite outcome of first confirmed virologic failure 
(VF), or discontinuation of randomized NRTI assignment. The latter occurred when a 
participant randomized to the Omit NRTIs Arm started any NRTI or when a participant 
randomized to the Add NRTIs Arm never initiated NRTIs or permanently discontinued all 
NRTIs (event time was scheduled week). Virologic failure (event time was scheduled week 
of initial RNA) was defined when one of the following occurred (and was confirmed with a 
repeat RNA measurement): < 1 log10 copies/mL decrease from baseline at the week 12 visit, 
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virologic rebound >200 copies/mL after suppression to <200 copies/mL, lack of suppression 
to <200 copies/mL by the week 24 visit, or HIV -1 RNA level ≥200 copies/mL at the week 
48 visit. All potential regimen failure outcomes underwent review adjudicated by two non-
team members who were blinded to treatment assignment and study site. Plasma HIV-1 
RNA was measured (UltraSensitive Roche Amplicor HIV-1 Monitor assay) at Johns 
Hopkins University. The primary safety outcome was time from treatment start to first 
Grade 3 or 4 sign, symptom, or laboratory abnormality that was at least one grade higher 
than baseline, while the participant was receiving the randomly assigned treatment. Adverse 
events were graded using the Division of AIDS (NIAID, NIH) Table for Grading the 
Severity of Adult and Pediatric Adverse Events, Version 1.0 - December 2004. Secondary 
outcomes reported here include the following: time from randomization to discontinuation 
of randomized NRTI assignment; time from randomization to confirmed virologic failure; 
probability of plasma HIV-1 viral load <50 copies/mL at weeks 24 or 48; probability of self-
reported non-adherence to ARV regimen (excluding NRTIs) at weeks 24 or 48; change in 
CD4 cell count from baseline to weeks 48; occurrence of newly acquired HIV drug 
resistance between treatment dispensation and confirmed virologic failure. Secondary 
outcomes not reported here include the following: time from treatment start to first ARV 
modification excluding NRTIs; change in cardiovascular risk score from baseline to weeks 
24 and 48; time from treatment dispensation to serious non-AIDS-defining events; change in 
fasting non-HDL cholesterol from baseline to weeks 24, 48; and week 96 outcomes.
Statistical Analysis
Based on a planned sample size of 177 participants per arm, the study had 80% power to test 
for non-inferiority of omitting versus adding NRTIs, with a 1-sided significance level of 
2.5%, assuming a failure rate of 35% in each arm, and a non-inferiority margin of 15%. The 
non-inferiority margin of 15% points was chosen to yield a feasible study design together 
with a clinically significant margin. Analyses were performed with SAS software, version 9 
(SAS Institute, Cary, North Carolina).
The cumulative probability of regimen failure by week 48 (primary outcome) was estimated 
using a stratified Kaplan-Meier estimator, with strata defined by the four unique ENF/INST 
experience by MVC-containing regimen groups. These estimates were found by weighting 
the stratum specific estimates (Proc LIFETEST), by treatment group, using inverse variance 
weights. Confidence intervals were calculated using the log(-log) transformed Greenwood 
estimated variance. Participants without regimen failure who left the study prior to week 48 
were censored at scheduled week of the last observed visit.
If the upper 95% confidence bound of the stratified difference in cumulative probability of 
regimen failure between Arms (Omit NRTIs – Add NRTIs) at week 48 were less than 15%, 
then non-inferiority would be concluded. Tests for statistical interactions between baseline 
characteristics and treatment effect used a stratified logistic regression model (PROC 
LOGISTIC).
Safety analyses used superiority hypotheses and stratified log-rank tests (PROC 
LIFETEST). Due to similarity in results whether stratified or not, cumulative incidence (K-
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M) plots for time to the various safety outcomes are unadjusted for strata and estimated 
cumulative probabilities of events by week 48 were not adjusted for strata.
Between arm comparisons for secondary outcome of changes in CD4 cell count to week 48 
used a stratified extension to Wilcoxon–Rank Sum test called van Elteren’s test (PROC 
FREQ). The secondary outcome of an HIV-1 RNA level of <50 copies/mL was compared 
between arms at week 48 with the use of an exact Cochran-Mantel-Haenszel test (PROC 
MULTTEST)). All participants with outcomes at week 48 (or baseline and week 48 for 
CD4), were included in these secondary analyses. Those persons in follow-up at week 24 or 
week 48 who were missing adherence data (and did not report a reason for missed data) 
were counted as having missed one or more doses of chosen ARV regimen.
Reported P values are two-sided. Secondary outcomes evaluated between weeks 48 and 96 
are not presented. Results from 53 non-randomized participants with a cPSS ≤2.0 are not 
presented.
Study conduct, safety, and efficacy data were reviewed yearly by an independent NIAID 
Data and Safety Monitoring Board.
RESULTS
Study Participants
Participants were enrolled between March 2008 and May 2011 at 62 centers in the United 
States with follow up through 48 weeks completed by May 31, 2012. Of 720 potential 
participants screened for resistance testing, 516 were available for randomization eligibility 
screening (Figure 1) and, 360 were randomized. Fifty-three participants could not be 
randomized because of a cPSS ≤ 2.0 but were assigned treatment with an optimized regimen 
and NRTIs (data not presented). Baseline characteristics were similar between randomized 
arms (Table 1).The median cPSS (excluding NRTIs) of chosen regimens was 3.0. Median 
number of active NRTIs was 1.0. The most common ARV regimen was RAL plus RTV-
boosted DRV with ETR (56%); in the arm randomized to Add NRTIs, 81% of participants 
used tenofovir (TDF) plus emtricitabine (FTC) (or lamivudine [3TC]) (Supplement Table 3). 
Note that randomization to the Add NRTIs arm occurred after selection of the optimized 
regimen and NRTIs. Three participants did not start study treatment. A total of 337 (94%) 
participants completed follow-up, and at each of the eight visits over 48 weeks, at least 95% 
of participants completed a study visit. In the Add NRTIs arm, 90% of participants reported 
taking NRTIs for at least 42 weeks. In the Omit NRTIs arm 26 (15%) participants reported 
missing one or more doses of their chosen ARV regimen by 4-day recall versus 25 (15%) 
from the Add NRTIs arm at week 24. Results were similar at week 48 (26 (16%) in Omit 
NRTIs arm, and 30 (18%) in Add NRTIs arm).
Primary Outcome of Regimen Failure
There were 53 regimen failures in the Omit NRTIs Arm and 48 in the Add NRTIs Arm 
(Figure 2). Only 5 participants left the study prior to week 48 and were not adjudicated as 
regimen failures. The estimated cumulative probabilities of regimen failure by week 48 were 
29.8% and 25.9% in the Omit and Add NRTIs Arms, respectively (estimated difference= 
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3.2%; 95% CI: −6.1, 12.5), allowing for the conclusion of non-inferiority between arms. The 
time to regimen failure was not different between the Omit versus Add NRTIs arms 
(stratified log-rank P = 0.50, Supplement Figure 1). Of the 101 regimen failure events, 83 
were triggered by virologic failure (41 in the Omit and 42 in the Add NRTIs arm), 16 were 
triggered by NRTI strategy discontinuation (10 and 6 respectively, see Supplement Table 4) 
and 2 had both concurrently (Omit NRTIs arm). The separate endpoints of confirmed 
virologic failure and NRTI strategy discontinuation each demonstrated non-inferiority of the 
Omit NRTI randomized arm (Figure 2).
When the primary endpoint of regimen failure was examined by sex, race, number of active 
NRTIs, viral tropism, stratification factors, cPSS of the regimen, or the use of ENF, there 
was no evidence of significant differences in treatment effect (Supplement Figure 2).
HIV-1 RNA AND CD4 Cell Count Changes Over Time
In the Omit NRTIs Arm, 64% (95% CI: 56%, 72%) of participants with available HIV-1 
RNA results had <50 copies/mL at week 48, compared to 66% in the Add NRTIs Arm (95% 
CI 59% to 73%, Figure 3A; P =0.73). Among those with baseline and week 48 values, the 
median CD4 increase from baseline to week 48 (Figure 3B) was 90 cells/mm3 (IQR, 
33-167) in the Omit NRTIs arm and 106 cells/mm3 (IQR, 46-214) in the Add NRTIs arm (P 
= 0.112).
Adverse Events and Changes in Creatinine and Lipids
The estimated probability of a primary safety event was 38% (95% CI: 32%, 46%; Figure 
4A) in the Omit NRTIs arm versus 35% (95% CI: 28%, 43%) in the Add NRTIs arm (P = 
0.93). Time to first severe or worse sign or symptom was not significantly different between 
arms. (P = 0.149; Figure 4B and Supplement Table 5). The Omit NRTIs arm had a non-
significantly shorter time to first severe or worse laboratory abnormality compared to the 
Add NRTIs arm (P = 0.093; Figure 4C), related primarily to lipid elevations. Grade 3 or 
higher hepatic abnormalities were rare (4% and 2% in the Omit versus Add NRTIs Arm) as 
were creatinine elevations (2% in each arm). Larger increases in lipid values were seen in 
the Omit compared to Add NRTIs arm, while creatinine clearance changes were not 
significantly different between arms (Supplement Table 6).
Serious Adverse Events and Deaths
Thirty-seven (21%) and 44 (24%) participants in the Omit and Add NRTIs Arms 
experienced a serious adverse event (SAE), respectively. Three SAEs in the Omit and 13 
SAEs in the Add NRTIs arms were thought to be at least possibly related to ARV therapy.
Following treatment initiation, there were no deaths in the Omit NRTIs arm and 6 deaths in 
the Add NRTIs arm (3.3 deaths per 100 person-years; 95% CI: 1.5, 7.4). The causes of death 
were: 1) heart failure in a participant with lymphoma (week 9 on study treatment), 2) 
Listeria meningitis (week 17), 3) renal failure (week 21), 4) sepsis with liver failure (week 
25), 5) progressive multifocal leukoencephalopathy (week 30), and 6) abdominal bleed in a 
participant with HCV and cirrhosis (week 52). Three deaths occurred during the pre-
randomization screening period (median follow-up of 63 days), when all participants 
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(n=516) continued on an NRTI-containing regimen, yielding an incidence of death prior to 
study enrollment of 4.2 per 100 person-years (95% CI: 1.3, 12.9).
Emergence of HIV-1 Drug Resistance among Participants with Virologic Failure
In the Omit NRTI arm, resistance to ETR developed in 9 of 43 (21.0%) participants who 
underwent resistance testing following virologic failure. In the Add NRTI arm 13 of 45 
(29.0%) virologic failure participants developed ETR resistance and 5 of 45 (11.0%) had 
decreased susceptibility to TDF. Emergence of resistance to other study ARVs was rare.
Of the 177 participants with R5 tropic virus during screening, 70% (124/177) chose a MVC-
containing regimen. Twenty-two percent (27/124) of participants on MVC experienced 
virologic failure, which was similar to the 21% (11/53) virologic failure rate among 
participants who were eligible, but did not choose a MVC-containing regimen. Among the 
participants choosing MVC who experienced virologic failure and had viral tropism results, 
5/26 (19%) had a shift to dual-mixed virus.
Discussion
The OPTIONS trial was a multicenter, randomized study in treatment-experienced patients 
failing their current PI-based therapy that included NRTIs, demonstrated that the addition of 
NRTIs, the cornerstone of initial ARV regimens (1), can be safely omitted if a new 
optimized regimen contains multiple fully or partially active ARV medications with a cPSS 
> 2.0. Most participants in this trial chose a regimen with 3-4 ARVs with partial or full 
activity. Through 48 weeks of follow-up, regimen failure, which combined confirmed 
virologic failure and discontinuation of the NRTI assignment, was not more likely if NRTIs 
were omitted from the new optimized regimens. The non-inferiority conclusion was robust 
and consistent across sensitivity analyses including analysis of the separate components of 
the primary regimen failure endpoint. No significant differences in regimen failure between 
arms were observed in subgroups of participants defined by stratification factors, 
demographics, or initial cPSS <3.0. Furthermore, HIV RNA suppression to <50 copies/mL, 
CD4 cell count gain, and time to regimen failure were similar in the Omit and Add NRTI 
arms. Therefore, among treatment-experienced patients starting an ARV regimen with a 
cPSS >2.0, there is strong and consistent evidence that adding NRTIs is not necessary to 
achieve optimal outcomes.
This study adds substantially to our knowledge of optimal therapy for treatment-experienced 
patients. In small and observational studies, NRTI-sparing regimens showed promise for 
treatment of patients with ARV drug resistance (5-8). In two large, randomized studies 
conducted in resource-limited settings for virologic failure of a first-line NNRTI regimen, 
RAL plus lopinavir/ritonavir (LPV/r) was non-inferior to 2 NRTIs plus LPV/r (9-10). 
Studies evaluating new regimens in treatment-experienced participants with limited options 
had only few patients taking NRTI-sparing regimens (11-14). For example, in the TRIO 
study, which evaluated DRV + ETR + RAL in experienced patients, only 16% received a 
regimen without NRTI (14). Thus, that trial could not answer whether NRTIs should be 
included in ARV-experienced patients starting several active agents.
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There were an unexplained greater number of deaths in the Add NRTIs arm compared to the 
Omit NRTIs arm. The causes of death were similar to those described in large HIV cohort 
studies (5-18) and could not be clearly attributed to NRTI toxicities. The small number of 
events limits our ability to conclude that omitting NRTIs leads to reduced mortality.
There some limitations to this study. The role of adding NRTIs to a regimen when the cPSS 
is ≤ 2.0 was not analyzed. Adding NRTIs may be helpful in persons with a cPSS <2.0. Also, 
the minimum number of active ARVs required in an optimized regimen without NRTIs is 
unknown. These results may not apply to resource poor settings where genotypic/phenotypic 
testing and tropism assays are not available. Finally, study treatment was not blinded to 
participants and investigators.
Long-term toxicities of NRTIs include decreases in bone mineral density, nephrotoxicity, 
and potential increased risk of myocardial infarction (19-21). However, over 48 weeks, we 
did not observe a significant reduction in adverse events within the omit NRTIs arm.
Conclusions
In ARV-experienced patients, NRTIs can be safely omitted from new active regimens 
provided the cumulative activity of the regimen exceeds that of two fully active agents as 
measured by current genotypic/phenotypic testing, tropism assay and accounting for prior 
treatment history. The potential benefits of omitting NRTIs include reduced pill burden, 
reduced cost and, likely, a decrease in NRTI-associated toxicity over the long-term. These 
results have been incorporated in recent ARV guideline recommendations for treatment of 
ARV-experienced patients (2).
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Refer to Web version on PubMed Central for supplementary material.
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Participant Disposition (CONSORT diagram). The progress of all participants from 
screening through randomization and analysis are displayed. Key outcomes are identified 
within each block. Populations for key analyses are also summarized.
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Primary outcome of regimen failure and its individual components (cumulative number of 
confirmed virologic failures and discontinuations of NRTI assignment). Because a 
participant may experience both virologic failure and discontinuation of the NRTI 
assignment, the number of events of the components exceeds the total number of regimen 
failures. Cumulative probabilities of outcomes by week 48 are given within the parentheses 
in the table (e.g., 29.8% regimen failure in the Omit NRTI arm). Between arm differences 
(Omit – Add NRTIs) in the cumulative probabilities with 95% CI are given in the right-most 
column and are plotted with the black squares and horizontal lines. The non-inferiority 
margin is denoted by the dashed vertical line. NRTIs = nucleoside reverse transcriptase 
inhibitors.
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Figure 3A. Proportion of participants with HIV-1 RNA <50 copies
Missing RNA values were excluded. The point estimate (circle) and 95% point-wise CI 
(vertical lines) are shown. 95% CIs calculated using normal approximation to the binomial. 
The number of observations in each group for each study week is also presented. All 
participants in each randomized arm were assessed at Week 0 (Omit NRTIs, N=179; Add 
NRTIs, N=181).
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Figure 3B. CD4 cell count changes from baseline for the randomized study arms
The median change (circles) and IQR (lines) are plotted by scheduled study visit. The 
number of observations in each group for each study week is also presented.
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Figure 4A. Primary safety outcome: Time to first Grade 3 or 4 sign or symptom, or laboratory 
abnormality that was at least one grade above baseline
The results presented are an as-treated analysis (including only those who started study 
treatment; events occurring after discontinuation of NRTI assignment are censored).
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Secondary safety outcome: Time to the first Grade 3 or 4 sign or symptom that was at least 
one grade above baseline. As-treated analysis (including only those who started study 
treatment, and events occurring after NRTI strategy discontinuation are censored).
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Secondary safety outcome: Time to the first Grade 3 or 4 laboratory abnormality that was at 
least one grade above baseline. As-treated analysis (including only those who started study 
treatment, and events occurring after NRTI strategy discontinuation are censored).
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TABLE 1
Baseline Characteristics of Study Population
Characteristic Omit NRTIs Add NRTIs Total
N=179 N=181 N=360
Sex: number (%)
   Female 47 (26%) 46 (25%) 93 (26%)
Age: years
   Median (Interquartile range) 46 (40-51) 46 (41-52) 46 (40-52)
Race/ethnicity: number (%)
   White 55 (31%) 59 (33%) 114 (32%)
   Black 69 (39%) 79 (44%) 148 (41%)
   Hispanic 46 (26%) 37 (21%) 83 (23%)
   Other* 8 (4%) 4 (2%) 12 (3%)
HIV-1 RNA (log10 copies/mL)
   Median (Interquartile range) 4.2 (3.6-4.6) 4.2 (3.6-4.7) 4.2 (3.6-4.6)
HIV-1 RNA level: number (%)
   < 50,000 copies/mL 148 (83%) 139 (77%) 287 (80%)
   ≥ 50,000 copies/mL 31 (17%) 42 (23%) 73 (20%)
CD4 count (cells/mm3)
   Median (Interquartile range) 212 (105-348) 193 (104-376) 207 (105-363)
Hepatitis C: number (%) 19 (11%) 27 (15%) 46 (13%)
Reported history of AIDS: number (%) 80 (45%) 90 (50%) 170 (47%)
Years on ARV: Median (Interquartile range) 12 (9-16) 10.7 (7.5-14) 11.4 (8.3-15)
Years on PIs: Median (Interquartile range) 9.4 (6-11) 8.4 (5-10.8) 9 (5.3-11)
Years on NNRTI: Median (Interquartile range) 1.9 (1.0-3.8) 2 (0.9-3.5) 1.9 (0.9-3.7)
Prior use of enfuvirtide: Number (%) 32 (18%) 29 (16%) 61 (17%)
Prior use of any integrase inhibitor: Number (%) 5 (3%) 4 (2%) 9 (3%)
HIV-1 tropism CCR5 only: Number (%)** 88 (49%) 89 (49%) 177 (49%)
Sensitive to NRTI ***
   Tenofovir 120 (67%) 117 (65%) 237 (66%)
   Lamivudine 55 (31%) 52 (29%) 107 (30%)
   Emtricitabine 52 (29%) 52 (29%) 104 (29%)
   Zidovudine 66 (37%) 78 (43%) 144 (40%)
   Abacavir 83 (46%) 92 (51%) 175 (49%)
Sensitive to Etravirine** 161 (90%) 162 (90%) 323 (90%)
Sensitive to specific protease inhibitors**
   Darunavir/ritonavir 135 (75%) 135 (75%) 270 (75%)
   Tipranavir/ritonavir 109 (61%) 108 (60%) 217 (60%)
Median regimen cPSS of selected regimen 3 3 3
   minimum- maximum 2.4-4 2.3-4 2.3-4
Median active NRTIs of selected NRTI 1 1 1
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Characteristic Omit NRTIs Add NRTIs Total
   Interquartile range 1-2 1-2 1-2
   minimum- maximum 0-3 0-3 0-3
*
Race missing for 1 in Omit and 2 in Add NRTIs.
**
Overall, 5% CXCR4 only and 6% non- reportable.
***
Sensitive determined by the Monogram “net assessment” which considers both the genotype and phenotype in determining resistance 
(categorized as sensitive, possible resistance or resistant). Susceptibility reported here is the sensitive category. ARV-Antiretrovirals, PI-Protease 
inhibitors, NNRTI-Non-nucleoside reverse transcriptase inhibitors, NRTI-Nucleoside/tide reverse transcriptase inhibitors, cPSS-Continuous 
phenotypic susceptibility score.
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